Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma
European Journal of Radiology · 2026-06 · 199 · 112784
DOI: 10.1016/j.ejrad.2026.112784 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Radiology, 2026-06. Verfasst von Yangyang Ou und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary & Vascular Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530007, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Protein Kinase Inhibitors. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province.
Abstract (Originalsprache)
BACKGROUND For patients with unresectable hepatocellular carcinoma (uHCC), the novel regimen of combining transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC), supplemented by immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs), has brought new hope for treatment. However, individual differences are significant. Some patients do not benefit from the treatment but instead bear the toxicity of the drugs and the economic burden. Accurate prediction of early treatment responses is key to optimizing strategies. METHODS A total of 205 patients with uHCC who underwent TACE-HAIC combined with ICIs and TKIs therapy were retrospectively enrolled from two independent institutions. A predictive model for early tumor response was developed based on enhanced CT imaging features, hepatic digital subtraction angiography (DSA) characteristics, and clinical parameters. The predictive performance of various models was systematically compared and evaluated. RESULTS Two clinical features, nine radiomics features, and eleven DSA features were included in the construction of the combined model. The prediction model exhibited robust performance, with an area under the receiver operating characteristic curve (AUC) of 0.944 (95%CI: 0.897-0.989) in the training cohort, 0.916 (95%CI: 0.832-0.997) in the internal validation cohort, and 0.902 (95%CI: 0.826-0.979) in the external validation cohort. This combined model has excellent calibration, and the analysis of the decision curve shows that it has extensive clinical practical value. CONCLUSIONS This study developed a multimodal predictive model integrating hepatic DSA, CT imaging, and clinical data for the prediction of early tumor response to TACE-HAIC combined with TKIs and ICIs in patients with uHCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary & Vascular Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530007, China.
- Department of Radiology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530007, China.
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, China.
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, China. Electronic address: zhongjianhong@gxmu.edu.cn.
- Department of Hepatopancreatobiliary & Vascular Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530007, China. Electronic address: yanyihe12@sr.gxmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
Zitieren
APA
Ou, Y., Yan, P., Liang, T., Chen, K., Lu, B., Dai, Y., Yang, D., Chen, Y., Cao, H., Yao, M., Guo, J., Liang, L., Li, J., Nong, Y., Chen, J., Huang, F., Zhong, J. H., & Yan, Y. (2026). Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma. European Journal of Radiology, 199, 112784. https://doi.org/10.1016/j.ejrad.2026.112784
Vancouver
Ou Y, Yan P, Liang T, Chen K, Lu B, Dai Y, et al. Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma. European Journal of Radiology. 2026;199:112784. doi:10.1016/j.ejrad.2026.112784
BibTeX
@article{Ou2026,
author = {Ou, Yangyang and Yan, Peng and Liang, Tianyi and Chen, Kang and Lu, Bingfeng and Dai, Yi and Yang, Dalong and Chen, Yiyu and Cao, Haizhao and Yao, Ming and Guo, Junjiang and Liang, Liang and Li, Jianjun and Nong, Yuanneng and Chen, Ji 'an and Huang, Fei and Zhong, Jian-Hong and Yan, Yihe},
title = {Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma},
journal = {European Journal of Radiology},
year = {2026},
volume = {199},
pages = {112784},
doi = {10.1016/j.ejrad.2026.112784}
}
EUVIMED